A new editorial paper was published in Oncoscience (Volume 11) on May 6, 2024, entitled, "Restoring our ubiquitination machinery to overcome resistance in cancer therapy."
In this new editorial, researchers Xiaoling Li and Ping Mu from the University of Southwestern Medical Center discuss the ubiquitin-proteasome system (UPS), which is usually responsible for regulating protein degradation, important for cellular homeostasis, and crucial in cancer progression. Its ability to regulate the stability of proteins that drive cancer growth and survival indicates its potential as a therapeutic target.
Among the UPS components, ubiquitin-conjugating enzymes, such as ubiquitin-conjugating enzyme E2 J1 (UBE2J1), have emerged as key players in cancer dynamics, especially in prostate cancer (PCa) where therapy resistance is a significant challenge.
"In our recent study, through a comprehensive in vivo library screening, we have identified the role of UBE2J1 in PCa, particularly its involvement in the degradation of the androgen receptor (AR)."
Source:
Journal reference:
Li, X., & Mu, P. (2024). Restoring our ubiquitination machinery to overcome resistance in cancer therapy. Oncoscience. doi.org/10.18632/oncoscience.600.
How different types of bread impact cancer risk